Circulation, Vol 73, 1334-1341, Copyright © 1986 by American Heart Association
ES Fain, P Dorian, JM Davy, RE Kates and RA Winkle
Encainide, a class IC antiarrhythmic agent, has been associated with
proarrhythmic responses of ventricular tachycardia and fibrillation
requiring defibrillation in patients. We examined the short-term effects of
intravenous encainide and its two major metabolites, O- demethyl-encainide
(ODE) and 3-methoxy-ODE (MODE), on the energy requirements for successful
defibrillation in 25 pentobarbital- anesthetized, open-chest dogs.
Truncated exponential (60% tilt) defibrillation shocks were administered
through right atrial spring and left ventricular epicardial patch
electrodes identical to those used in man with the automatic implantable
defibrillator. At baseline multiple shocks of varying energy were applied
to construct curves of percent successful defibrillation as a function of
energy (DF curves) for each animal. Encainide, ODE, or MODE was then
infused in loading and maintenance doses to achieve QRS widening of 20% to
50%. Saline was administered to animals serving as controls. Determination
of the DF curve was repeated, after which the infusion was discontinued.
After 1 hr washout period, an additional DF curve was constructed. The data
were analyzed by logistic regression, and the energies required for 50%
successful defibrillation (E50) were compared. No significant differences
existed between the four groups in body or heart weight, extent of QRS
widening, or baseline E50 values. After administration of encainide and
ODE, the E50 increased by 129 +/- 43% (p less than .001) and 76 +/- 34% (p
less than .005), respectively. Return of E50 toward baseline was observed
after the washout periods in both groups (p less than .025), demonstrating
the reversibility of the drugs' effects.(ABSTRACT TRUNCATED AT 250 WORDS)
ARTICLES
Effects of encainide and its metabolites on energy requirements for defibrillation
This article has been cited by other articles:
![]() |
L.-P. Lai, J.-L. Lin, W.-P. Lien, Y.-Z. Tseng, and S. K. S. Huang Intravenous sotalol decreases transthoracic cardioversion energy requirement for chronic atrial fibrillation in humans: assessment of the electrophysiological effects by biatrial basket electrodes J. Am. Coll. Cardiol., May 1, 2000; 35(6): 1434 - 1441. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Boriani, M. Biffi, A. Capucci, G. Bronzetti, G. M. Ayers, R. Zannoli, A. Branzi, and B. Magnani Favorable effects of flecainide in transvenous internal cardioversion of atrial fibrillation J. Am. Coll. Cardiol., February 1, 1999; 33(2): 333 - 341. [Abstract] [Full Text] [PDF] |
||||
![]() |
D A Chamberlain Antiarrhythmic drugs in resuscitation Heart, October 1, 1998; 80(4): 408 - 411. [Full Text] |
||||
![]() |
D. M. Roden Risks and Benefits of Antiarrhythmic Therapy N. Engl. J. Med., September 22, 1994; 331(12): 785 - 791. [Full Text] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1986 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |